English
|
Spanish
Login
Register
The content on this site is intended for healthcare professionals only
For the latest
e
cancer COVID-19 resources, click on this link
Home
News
Journal
Video
e
learning
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
e
cancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.
Please login or register. Then you can use this button to confirm you are part of this project.
Register for free
Already have an account?
Login
Videos
[1721]
News
[2697]
Articles
[105]
Editorials
[3]
Conferences
[89]
e
learning
[4]
EHA 2022: Magrolimab and azacitidine show durable responses and encouraging results in TP53-mutant A...
EHA 2022: Targeted therapy emavusertib shows encouraging activity in MDS and AML with specific mutat...
EHA 2022: Ponatinib and blinatumomab combination has high response rates for patients with PH+ ALL
EHA 2022: Ibrutinib combination with bendamustine-rituximab and rituximab maintenance as a first-lin...
EHA 2022: Decitabine shows similar survival and fewer adverse events compared to standard chemo in g...
EHA 2022: Quizartinib improves overall survival in adults with FLT3-ITD+ acute myeloid leukaemia
EHA 2022: A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/r...
EHA 2022: Improved progression-free survival is achievable using targeted therapy combinations with ...
Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy
Drugs used to treat blood cancer could activate “sleeping” cancer-causing gene
<
1
2
3
4
5
...
270
>
More from
e
cancer
